	US 12,222,351 B2
	Immunoassay and measurement reagent for leucine-rich alpha2 glycoprotein
Shigeo Takayama, Tokyo (JP); Tetsuji Naka, Ibaraki (JP); and Satoshi Serada, Ibaraki (JP)
Assigned to SEKISUI MEDICAL CO., LTD., Tokyo (JP); and NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION, Ibaraki (JP)
Appl. No. 17/282,307
Filed by SEKISUI MEDICAL CO., LTD., Tokyo (JP); and NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION, Ibaraki (JP)
PCT Filed Oct. 8, 2019, PCT No. PCT/JP2019/039564 § 371(c)(1), (2) Date Apr. 1, 2021, PCT Pub. No. WO2020/075691, PCT Pub. Date Apr. 16, 2020.
Claims priority of application No. 2018-190905 (JP), filed on Oct. 9, 2018.
Prior Publication US 2021/0382041 A1, Dec. 9, 2021
Int. Cl. G01N 33/545 (2006.01)

CPC G01N 33/545 (2013.01) [G01N 2400/00 (2013.01)]

11 Claims

1. An immunological measurement method for leucine-rich α2 glycoprotein (LRG) in a biologically derived sample comprising:

bringing the sample into contact with at least first insoluble carrier particles carrying a first anti-LRG monoclonal antibody and second insoluble carrier particles carrying a second anti-LRG monoclonal antibody in a liquid phase,

wherein the first and the second insoluble carrier particles are latex particles having average particle sizes of 100 nm to 340 nm, and

wherein the first and the second insoluble carrier particles are latex particles having critical coagulation concentrations of 65 mM to 270 mM.